

Curriculum vitae with track record, Tom Dønnem

Personal information

First name, Surname:	Tom, Dønnem		
Date of birth:	11.09.70	Sex:	Male
Nationality:	Norwegian		

Education

Year	Faculty/department - University/institution - Country
2013	Full Professor, University of Tromsø (UiT), Norway
2009	Ph.D., University of Tromsø (UiT), Norway
2005	Speciality of Oncology, UNN, Tromsø, Norway (Clinical)
1998	MD, University of Tromsø (UiT), Norway

Positions - current and previous

Year	Job title – Employer - Country
1998-2000	Internship, Elverum/Tromsø - Norway
2000-2005	Resident, Department of Oncology, UNN (100% position) - Norway
2005-	Senior Consultant Oncologist, Department of Oncology, UNN (20-40 % position) - Norway
2005-2009	Research fellow, Translation Cancer Research Group (TCRG), UiT/UNN - Norway
2009-2011	Postdoc,TCRG, UiT/UNN - Norway
2011-2012	Postdoc Translational cancer research group at Radcliffe Hospital, University of Oxford, UK (Headed by prof. Adrian L Harris and prof. Francesco Pezzella).
2013-	Professor and Head (100% position), TCRG, UiT/UNN - Norway
Autumn 2016	Visiting professor, University of Oxford, UK (Same group as in 2011-2012)

Awards

Year	
2009	Norwegian national cancer research award, “Young cancer researcher of the year” (Onkologisk Forum).

Career breaks

Year	Reason
Autumn 2020	Leave of absence (loss of son)

Project management experience

Year	Project owner - Project - Role - Funder
As main applicant and project leader (PI):	
2012	Research position (100%, 3 years) NCS 2.7 M NOK
2012	Research position (100%, 4 years) NNHA 3.6 M NOK
2013	PhD (100%, 3 years) NNHA 2.7 M NOK
2014	Postdoc (50%, 6 years) NHHA 2.7 M NOK
2015	Postdoc (70%, 4 years) NCS 2.6 M NOK
2016	Technician (100%, 2 years) + running costs NCS 2.6 M NOK
2017	Postdoc (50%, 6 years) NHHA 3.2 M NOK
2018	Postdoc (100%, 3 years) + running costs NCS 7.2 M NOK
2020	Local Infrastructure UNN/UiT, IMPRESS Study NHHA 10.4 MNOK
2022	Local Infrastructure UNN, clinical trials NCS 2.1 M NOK
2022	Local Infrastructure UNN, clinical trials JF 2.1 M NOK
As WP leader:	
2016	Lung cancer study (PI Sandanger) NCS 1.6 M NOK
2016	Lung cancer study (PI Sandanger) NRC 10.0 M NOK
2019	The NGS Expertise Group for Lung Cancer (PI Helland) NCS 15.0 M NOK
Abbreviations: NCS, Norwegian Cancer Society; NNHA, Northern Norway Health Authority; GF, Gaasland Foundation; NRC, Norwegian Research Council; JF, Jenny Louise Nilsens’ Foundation	

Supervision of students

Postdocs	Ph.D. students	Master's students	University/institution - Country
6	9	Approx. 10	UiT/UNN -Norway
Lecturing many health care professions for 20 years, last 3 years head of coordinating medical students' cancer related lectures/seminars/examens at UiT/UNN. Member of national exam committee last year medical students.			

Other relevant professional experiences

Year	Description - Role
2010-	Member of the translational subgroup of Norwegian Lung Cancer Group
2010-2014	Member of "King Olav Vth Cancer Research Prize" evaluating committee.
2010-2014	Member of revision group - national guidelines palliative care in Norway
2012-2019	Member leader group of Norwegian Cancer Genomics Consortium
2013-2016	Member of evaluating research committee of "Helse Sør-øst"
2013-2020	Member of national project group "microRNA profiling - Janus Serum Bank"
2013-2020	Council member of the national group: "Individual cancer treatment based on gene profile of the tumor"
2013-2019	Member of project group "The Norwegian Cancer Society's National Centre of expertise for lung cancer"
2016-	Member of Society of Immunotherapy in Cancer (SITC)
2016-	PI Prospective Nordic Multicentre TNM-I study
2019-2022	WP leader European ID-Lung Study
2019-	Member Advisory Board LETSGO study
2019-2022	Member Supervisory Board Norwegian Cancer Society
2020-	Member Trial Management Committee, IMPRESS Study
2020-	Member Leader Group "The Norwegian Cancer Society Expertise Group for Lung Cancer
2021-	Member Publication and Biobank Committee, IMPRESS-Norway
2022-	Evaluation Committee of professor positions at OUH
2022-	Member Scientific Board, The Norwegian Cancer Society

Ad hoc reviewer in several journals and opponent in Norway and Sweden

Track record - Publications

H-index (Google Scholar): 47

Number of citations (Google Scholar): > 7900

Number of citations last year (2023): 785

Publications last 10 years: 64

Total publications in PubMed: 110

10 publications as 1st author with > 100 citations

Relevant publications – last 10 years as 1st or last author:

#	Publication
1	Donnem T , Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, Gatter KC, Pezzella F. Vessel co- option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? <i>Cancer Medicine</i> 2013;2:427-436.
2	Donnem T , Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Pohl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sanager TM, Andersen S, Pezzella F, Bremnes RM, Busund LT. Stromal CD8+ T Cell Density - A Promising Supplement to TNM staging in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015;21:2635-43.
3	Donnem T , Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al- Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. <i>Annals of Oncology</i> . 2016;27:225-32.
4	Bremnes RM, Busund LT, Kilvør TL, Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehenkari MR, Cooper WA, Kao SC, Donnem T . The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. <i>J Thoracic Oncol</i> , 2016;11:789-800.
5	Paulsen EE, Kilvaer TK, Rakaee M, Richardsen E, Hald SM, Andersen S, Busund LT, Bremnes RM, Donnem T . CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. <i>Cancer Immunol Immunother</i> . 2017 Nov;66(11):1449-1461.
6	Donnem T , Reynolds AR, Kuczyński EA, Gatter K, Vermeulen PB, Kerbel RS, Harris AL, Pezzella F. Non-angiogenic tumours and their influence on cancer biology. <i>Nature Reviews Cancer</i> 2018 May;18:323-336.
7	Kilvaer TK, Paulsen EE, Andersen S, Rakaee M, Bremnes RM, Busund LR, Donnem T . Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer? <i>Carcinogenesis</i> . 2020 Dec 31;41(12):1671-1681.
8	Rakaee M, Kilvaer TK, Jamaly S, Berg T, Paulsen EE, Berglund M, Richardsen E, Andersen S, Al-Saad S, Poehl M, Pezzella F, Kwiatkowski DJ, Bremnes RM, Busund LR, Donnem T . Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. <i>Br J Cancer</i> . 2021 May;124(10):1680-1689.
9	Paulsen EE, Andersen S, Rakaee M, Pedersen MI, Lombardi AP, Pøhl M, Kilvaer T, Busund LT, Pezzella F, Donnem T . Impact of microvessel patterns and immune status in NSCLC: A non-angiogenic vasculature is an independent negative prognostic factor in lung adenocarcinoma. <i>Frontier in Oncology</i> 2023. Volume 13 – 2023.
10	Rakaee M, Andersen S, Giannikou K, Paulsen EE, Kilvaer TK, Busund LR, Berg T, Richardsen E, Lombardi AP, Adib E, Pedersen MI, Tafavvoghi M, Wahl SGF, Petersen RH, Bondgaard AL, Yde CW, Baudet C, Licht P, Lund-Iversen M, Grønberg BH, Fjellbirkeland L, Helland Å, Pøhl M, Kwiatkowski DJ, Donnem T . Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial. <i>Annals of Oncology</i> . 2023 Jul;34(7):578-588